ICI Europe Summit - Immune Checkpoint Inhibitors

Memo

With well over 2000 combination trials ongoing, phrases like 'hit-and-hope' and 'throwing anything together' seem much more common than 'logical' and 'rational'. To provide clarity through this fog of complexity, the upcoming ICI Europe conference is structured around engaging every stage in the cancer immunity cycle, providing a mechanistic framework to combination approaches. Get the full event guide to find out more: https://bit.ly/2xCZeR6 Rather than covering a random selection of immunooncology combinations, ICI Europe focuses on how checkpoint combinations can impact every stage of the cancer immunity cycle, enhancing the long term success of immuno-oncology drug development. Cutting through the noise and hype around the immunooncology field, this industry focused conference will use the cancer immunity cycle as a framework from which to investigate the most promising checkpoint combination approaches. Detailing combinations based exclusively on synergistic mechanisms rather than a ‘hit-and-hope’ combination approaches; however you're approaching the immunooncology space, learn how you can engage a checkpoint backbone to enhance combination success The 4th Annual ICI Europe 2018 is taking place in Berlin from 27-29 November. Prices: Platinum Delegate Pass: EUR 3497.0Gold Delegate Pass: EUR 2998.0Silver Delegate Pass: EUR 2599.0Bronze Delegate Pass: EUR 599.0 URLs: Brochure: https://go.evvnt.com/271384-0?pid=5569 Tickets: https://go.evvnt.com/271384-2?pid=5569 On Tuesday November 27, 2018 at 8:00 am (ends Thursday November 29, 2018 at 6:00 pm)  Venue details: Sofitel Berlin Kurfurstendamm, 41 Augsburger Straße, Berlin, 10789, Germany Speakers: Craig Blanchette, Senior Scientist, Genentech, Mathieu Blery, Senior Director, Translational Immunology, Innate Pharma, Jannie Borst, Head, Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Tanja de Gruijl, Professor, Translational Tumor Immunology, VU University Medical Center, Wolf-Dietrich Doecke, Director, Biomarker Strategist, Bayer, Walter Ferlin, Head of Exploratory Science and Translational Medicine, NovImmune, Tina Furebring, Vice President, Research and Development, Research, Alligator Bioscience, Laura Helming, Director, Scientific Site Head, Immuno-Oncology, Merck KGaA, Marlon Hinner, Group Leader, In Vitro Display, Roche, Christian Hosius, Regional Director, Medical Affairs, Oncology, Merck Sharpe and Dohme, Zoë Johnson, CSO, iOnctura, Reece Marillier, Research Scientists, In Vivo Pharmacology, iTeos Therapeutics, Nicolo Rigamonti, Biology Lead and Project Leader, Cancer Immunology, Molecular Partners, Kris Sachsenmeier, Associate Director, Translational Science, IMED Oncology, AstraZeneca, Zhen Su, Senior Vice President and Chief Medical Officer, NA, Merck KGaA, Tim Sullivan, Vice President, Business Development, Arcus Biosciences, Frederic Triebel, CSO and CMO, Immutep, Markus Zettl, Director, Immuno-Oncology, Pieris Pharmaceuticals